Biogen's acquisition of Apellis Pharmaceuticals

Biogen Inc. (NASDAQ:BIIB) announced on Tuesday, May 17, its acquisition of Apellis Pharmaceuticals Inc. (NASDAQ:APLS) for approximately $5.6 billion in cash, valuing APLS shares at $41 each, a 140% premium. This deal, expected to close in Q3 2022, adds C3 therapies to Biogen's portfolio, marking a strategic pivot away from its traditional strength in multiple sclerosis treatments.

The acquisition drove a significant market impact. Biogen stock rose 1.5% on Wednesday, while APLS shares surged to a two-year high, benefiting from the 140% upside. However, Biogen's stock also experienced volatility, dropping 2.5% on Monday due to anticipated higher spending on milestone payments and R&D activities. Biogen's quarterly updates have not been impressive, casting uncertainty over its long-term prospects.

Next, investors should watch for the closing of the acquisition in Q3 2022. Additionally, they should monitor Biogen's quarterly updates and earnings releases to assess the company's ability to drive top-line growth beyond regulatory progress. Lastly, the market will closely follow the integration of Apellis' C3 therapies into Biogen's portfolio and their potential impact on the company's future performance.